News
Novo Nordisk shares dropped as low as $46.90 in Thursday’s session, their lowest level since January 2022, following a profit warning.
Novo Nordisk slashed its financial forecasts as it struggled to fight off competition in the United States. It also named a ...
Some of the most recognizable brand names that could be impacted include Ozempic and Wegovy, two injectable drugs that have grown popular in recent years for their abilities to treat diabetes and ...
Novo Nordisk faces slowing demand, rising competition, and CEO transition. Learn about challenges impacting its growth and ...
Kumar now believes the stock is only worthy of a hold recommendation, down from his previous assessment of buy. He also significantly lowered his price target, chopping it to 360 Danish krone ($55.49) ...
Novo Nordisk said it expects weaker sales growth of its popular weight-loss drug Wegovy due to competition from copycat drugs ...
2don MSN
Shares in Novo Nordisk fell as much as 30% after it slashed sales and profits forecasts for the second time this year amid ...
A Lilly study showed Mounjaro resulted in a lower risk of heart attacks and strokes in patients with diabetes compared with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback